Zacks Research Issues Optimistic Outlook for UTHR Earnings

United Therapeutics Co. (NASDAQ:UTHR) – Stock analysts at Zacks Research upped their Q4 2024 earnings per share estimates for shares of United Therapeutics in a note issued to investors on Tuesday, November 19th. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings per share of $6.04 for the quarter, up from their prior estimate of $5.40. The consensus estimate for United Therapeutics’ current full-year earnings is $25.10 per share. Zacks Research also issued estimates for United Therapeutics’ Q3 2025 earnings at $7.33 EPS, Q4 2025 earnings at $6.74 EPS, FY2025 earnings at $27.64 EPS, Q3 2026 earnings at $7.15 EPS and FY2026 earnings at $26.89 EPS.

A number of other brokerages have also issued reports on UTHR. Wells Fargo & Company upped their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. HC Wainwright increased their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Jefferies Financial Group lifted their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $370.86.

United Therapeutics Stock Performance

UTHR stock opened at $372.89 on Friday. The company has a market capitalization of $16.65 billion, a PE ratio of 16.38, a price-to-earnings-growth ratio of 1.05 and a beta of 0.56. The company’s fifty day moving average price is $365.06 and its 200-day moving average price is $331.37. United Therapeutics has a one year low of $208.62 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. United Therapeutics’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same period last year, the business earned $5.38 EPS.

Insiders Place Their Bets

In related news, CEO Martine A. Rothblatt sold 269 shares of United Therapeutics stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the transaction, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $45,293.30. This trade represents a 67.42 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO James Edgemond sold 7,802 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $345.41, for a total value of $2,694,888.82. Following the completion of the transaction, the chief financial officer now directly owns 3,210 shares in the company, valued at $1,108,766.10. The trade was a 70.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 117,496 shares of company stock valued at $43,765,042 in the last three months. Company insiders own 11.90% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Comerica Bank lifted its stake in shares of United Therapeutics by 5.9% in the 1st quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after purchasing an additional 9,244 shares during the period. Tri Locum Partners LP acquired a new position in United Therapeutics in the second quarter valued at about $15,959,000. QRG Capital Management Inc. boosted its holdings in United Therapeutics by 12.4% during the second quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock worth $4,880,000 after buying an additional 1,692 shares during the last quarter. Canada Pension Plan Investment Board grew its position in shares of United Therapeutics by 567.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after buying an additional 153,700 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of United Therapeutics by 1.1% in the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock valued at $692,748,000 after acquiring an additional 22,978 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.